Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.38 |
| ▸ | CCR1 | P32246 | 2/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
| ▸ | CCR8 | P51685 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | METAP1 | P53582 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | DOHH | Q9BU89 | 1/20 | 0.38 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30462892 | 0.82 | ALOX5 (0.47) | ALOX5KDM4ELMNACCR1CCR5 | |
| SCHEMBL4072185 | 0.82 | ALOX5 (0.47) | ALOX5KDM4ELMNACCR1CCR5 | |
| SCHEMBL21392397 | 0.79 | KDM4E (0.45) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL28363259 | 0.79 | ALOX5 (0.43) | ALOX5KDM4ELMNACCR1CCR5 | |
| SCHEMBL29390749 | 0.79 | ALOX5 (0.43) | ALOX5KDM4ELMNACCR1CCR5 | |
| SCHEMBL19794966 | 0.74 | DRD1 (0.36) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL4072186 | 0.73 | ALOX5 (0.52) | ALOX5KDM4ELMNACCR1CCR5 | |
| SCHEMBL16889957 | 0.72 | KDM4E (0.35) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL16889464 | 0.72 | KDM4E (0.37) | KDM4ELMNACCR1CCR5CCR8 | |
| SCHEMBL19794965 | 0.71 | HTR7 (0.40) | KDM4ELMNACCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2009-08-27 | — | — | US | disclosed |
| EP-1874731-A4 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS INC (US) | 2009-08-05 | — | — | EP | disclosed |
| US-7402579-B2 | Quinobenzoxazine analogs and compositions | CYLENE PHARMACEUTICALS, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| EP-1874731-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | Cylene Pharmaceuticals, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYLENE PHARMACEUTICALS, INC. | 2006-11-23 | — | — | US | disclosed |
| WO-2006113509-A2 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYLENE PHARMACEUTICALS, INC. (US) | 2006-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264634-A1 | Quinobenzoxazine analogs and methods of using thereof | CYP2W1, NQO2, UGT2B7 | ALOX5 329/4885KDM4E 1852/4885LMNA 2466/4885 |
| US-20090215761-A1 | QUINOBENZOXAZINE ANALOGS AND METHODS OF USING THEREOF | CYP2W1, NQO2, UGT2B7 | ALOX5 329/4885KDM4E 1852/4885LMNA 2466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.